Copper transport and its alterations in Menkes and Wilson diseases  by DiDonato, Michael & Sarkar, Bibudhendra
ELSEVIER Biochimica et Biophysica Acta  1360 (1997)  3 -16  
BIOCHIM1CA ET BIOPHYSICA AC'TA 
BBN 
Rev iew 
Copper transport and its alterations in Menkes and Wilson diseases 
Michae l  D iDonato  a,b, Bibudhendra Sarkar a,b,* 
a Department ofBiochemistry Research, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G IX8, Canada 
b Department ofBiochemist~, University of Toronto, Toronto, Ontario M5S 1A8, Canada 
Received 8 July 1996; revised 1 November 1996; accepted l November 1996 
Contents 
1. In t roduct ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
2. Normal copper transport . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
2.1.  Transport across the gastrointestinal tract and in blood . . . . . . . . . . . . . . . . . . . . . .  
2.2.  Membrane transport . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
2.3.  In t race l lu la r  copper transport . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
2.4.  Transport phenomena in excretion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
3. Wilson disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
4. Menkes disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
5. Future perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
3 
4 
4 
5 
6 
6 
6 
l0  
13 
13 
13 
1. Introduction 
The recent discovery of the genes for Menkes and 
Wilson diseases [1-7] is a major breakthrough in our 
understanding of the phenomenon of copper trans- 
port. The findings have generated renewed interests 
in the studies of the transport mechanism of not only 
* Corresponding author. Please address correspondence to first 
address. Fax:  + 1 416  8135379.  
copper but also other essential trace elements. The 
transport process is vitally important to sustain life. 
The essential function of copper is being played by 
its presence as an integral part of the active sites of 
many enzymes (Table 1). While trace amounts of 
copper are essential for life, amounts in excess of the 
needs are toxic and have deleterious effects in living 
tissues. Major efforts have been made by many labo- 
ratories to understand the intricate and specific mech- 
anisms by which copper is made available to perform 
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Table 1 
Copper-containing enzymes in humans 
Reaction catalyzed 
Oxidoreductases 
Cu, Zn superoxide dismutase (EC 1.15.1.1 ) 
Lysyl oxidase (EC 1.4.3.13) 
Amine oxidase (EC 1.4.3.6) 
Cytochrome c oxidase (EC 1.9.3.1) 
Ceruloplasmin (EC 1.16.3.1) 
Monooxygenases 
Yyrosinase (EC 1.14.18.1 ) 
Dopamine/3-hydroxylase (EC 1.14.17.1) 
Peptidylglycine monooxygenase (EC 1.14.17.3) 
O2- + O2- + 2H+---~ O2 + H202 
peptidyl-L-lysyl-peptide + H20 + 0 2 ~ peptidyl-allysyl-peptide + NH 3 ÷ H202 
RCH2NH 2 + H20 ~ RCHO + NH 3 + H202 
4 ferrocytochrome c + O 2 -~ 4 ferricytochrome c + 2 H20 
4 Fe(II) + 4 H + + O 2 --* 4 Fe(III) + 2 H20 
L-tyrosine + L-dopa + 0 2 --> L-dopa + dopaquinone + H20 
dopamine + ascorbate + 02 ~ noradrenaline + dehydroascorbate + H20 
peptidylglycine + ascorbate + 02 ~ peptidyl(2-hydroxyglycine) + 
dehydroascorbate + H 2 ° 
its essential function in the cells and whereby the 
accumulation of excessive amounts of copper be- 
comes toxic. There are excellent reviews written in 
recent years which addresses various aspects of cop- 
per transport [8-12]. In this review we will discuss 
the normal transport of copper in relation to its 
absorption, its movement in blood and tissues and its 
excretion. Major emphasis i  given in presenting the 
clinical features associated with the alterations of the 
copper transport processes in Menkes and Wilson 
diseases in light of the newly discovered genes of 
these two hereditary diseases. 
2. Normal copper transport 
2.1. Transport across the gastrointestinal tract and in 
blood 
Copper absorption is limited to the stomach and 
small intestine. Transport from the intestinal lumen 
into intestinal mucosa is a carrier mediated process 
involving a saturable transport component [13,14]. 
The overall intestinal copper uptake is influenced by 
amino acids [15], ascorbic acid [16] and other dietary 
factors. Sulfide anion has been shown to markedly 
diminish absorption of copper in humans [17]. Both 
zinc [18] and cadmium [19] inhibit intestinal copper 
uptake. The intestinal metallothionein may have some 
function in maintaining copper homeostasis. Cerulo- 
plasmin is the major copper-protein in blood plasma. 
But copper in ceruloplasmin is not exchangeable [20]. 
There is, however, 5-10% of copper bound to non- 
ceruloplasmin forms which is exchangeable. Bearn 
and Kunkel [21] first demonstrated that copper in 
plasma was bound to albumin. As early as 1954 Earl 
et al. [22] reported that 0.2-0.4% of unspecified 
amount of labeled copper added in vitro to human 
serum was ultrafiltrable. But it was not until the 
reports of Sarkar and Kruck [23] and those by Neu- 
mann and Sass-Kortsak [24] that the true nature of 
these low molecular weight copper-binding sub- 
stances became known. Neumann and Sass-Kortsak 
[24] presented the evidence for an amino acid-bound 
fraction by reconstitution experiments whereas Sarkar 
and Kruck [23] actually detected and isolated 
copper-amino acid complexes from normal human 
blood serum and showed that the main complex was 
in the form of 1:2 copper-histidine complex. 
Further studies revealed that human albumin has 
one strong copper-binding site and that it formed a 
ternary complex between albumin copper and histi- 
dine [25,26]. Albumin may play a regulatory role in 
controlling the flow of copper between the plasma 
compartment and tissues. Histidine competed favor- 
ably with albumin for copper and the ternary com- 
plex was found to be the rate determining step in the 
exchange of copper between histidine and albumin 
[27-29]. This finding was critical in initialing a 
treatment for Menkes disease by copper-histidine 
[30-34]. Results from various laboratories have 
shown that copper in the form of copper-histidine is 
taken up by cells [35-40]. The structure of the copper 
binding site of human albumin has been characterized 
[41-44]. A high molecular weight protein, trans- 
cuprein has been implicated as a copper carrier in 
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plasma [45,46]; the characterization f  this protein is 
awaited. 
2.2. Membrane transport 
There are at least two pathways by which copper is 
transported across the membrane (Fig. 1). Ceruloplas- 
min, the most abundant copper-protein plasma, can 
contribute copper to cells [40,47-50]. Studies of 
ceruloplasmin mediated copper transport in cells have 
shown that copper derived from ceruloplasmin enters 
the cell but the protein does not [51]. Stimulation of 
copper uptake by ascorbate and the inhibition of the 
process by cuprous chelators suggest that copper 
uptake takes place in the form of Cu(I) rather than as 
Cu(II) [52,53]. It should be pointed out that evidence 
suggest hat ceruloplasmin also possesses ferroxidase 
activity [54,55]. Potential ceruloplasmin receptors on 
several cell types and tissues have been reported 
[56-60]. Much work remains to be carried out with 
ceruloplasmin mediated copper transport involving 
these receptors. The second route of copper transport 
across membrane is through 'mobile' pathway repre- 
senting histidine, albumin or other non-ceruloplasmin 
copper [35,36]. Histidine and albumin have two dif- 
ferent effects [40]. Histidine enhances the copper 
uptake whereas albumin inhibits it. Histidine has 
been shown to enhance the uptake of copper in 
human trophoblast cells in the presence of serum 
which is considered to be due to the release of copper 
that is bound to albumin [40]. As has been stated 
previously, the ternary complex albumin-copper- 
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Fig. 1. Normal copper transport. Copper is absorbed from the gastrointestinal tract and enters the exchangeable copper pool. This pool 
consists of copper bound to albumin, and low-MW amino acid complexes in the Cu(II) form. During uptake, copper is reduced to Cu(I) 
by a hypothetical membrane r ductase and is absorbed by the cell through a passive transporter. Copper from ceruloplasmin (Cp) may 
also be taken up by cells. In this pathway Cp interacts with a cell surface receptor and its copper atoms are reduced to Cu(I) by a 
membrane r ductase. Cu(I) is then taken up by the cell by passive transport. Upon entering the cytoplasm copper may be complexed to a 
variety of ligands. However, it is thought hat the majority of cytoplasmic copper is complexed to glutathione (GSH) as Cu(I). The 
Cu(I)-GSH complex can then donate copper to various intracellular proteins uch as superoxide dismutase (SOD) and metallothionein 
(MT). The Wilson copper-ATPase which may be positioned in the membrane of the golgi, is responsible for providing copper to the 
necessary proteins in the excretory pathway such as ceruloplasmin. This ATPase may also be involved in moving copper atoms across the 
canilicular membrane and into bile. 
6 M. DiDonato, B. Sarkar/Biochimica et Biophysica Acta 1360 (1997) 3-16 
histidine may play an important role in such ex- 
change processes [25,26]. Further research is war- 
ranted to delineate this mechanism of copper trans- 
port. 
2.3. Intracellular copper transport 
Copper is distributed in all cellular organelles in- 
cluding the nucleus, mitochondria, lysosomes, endo- 
plasmic reticulum and cytosol [61]. Copper proteins 
are located in all cellular compartments: superoxide 
dismutase in the cytosol and possibly peroxisomes 
[62], cytochrome c oxidase in the mitochondria [63] 
and lysyl oxidase [64] in the Golgi and secretory 
organelles, metallothionein the cytosol, nucleus 
and lysosomes [65,66]. The intracellular copper trans- 
port is vital to the delivery of copper to copper-pro- 
teins. Among all the transport processes of copper, 
intracellular transport of copper is the least under- 
stood area. Once copper is absorbed in the cell some 
of it is effluxed from the cell. Glutathione (GSH) has 
been implicated as the main chelator of copper in the 
cytoplasm. Studies on copper loaded hepatoma cells 
have indicated that over 60% of cytosolic copper 
exists as a Cu(I)-GSH complex [67]. Furthermore, it 
has been shown that Cu(I)-GSH is able to fully 
reconstitute apo-superoxide dismutase, apo-metal- 
lothionein, and apo-ceruloplasmin in vitro [68-70]. 
Efflux is facilitated by P-type ATPase which will be 
discussed in detail further on. The P-type ATPases 
coded by the Wilson and Menkes disease genes, may 
also play a role in transporting copper across the 
membranes on the golgi or endoplasmic reticulum for 
incorporation i to newly synthesized proteins. Local- 
ization of these ATPases in the cell will be an 
integral part in elucidating the role these proteins 
play in the normal intracellular t ansport of copper. 
2.4. Transport phenomena in excretion 
The main route of excretion of copper from the 
body is bile [71]. Bile contains both low molecular 
weight copper-binding compounds as well as high 
molecular weight species [72]. The low molecular 
weight components are more prevalent in hepatic bile 
and the high molecular weight fraction predominates 
in gall bladder bile. The fraction of biliary copper in 
marcomolecular-bound form may arise from copper 
that permeates the bile canaliculus and subsequently 
binds non-specifically with proteins in the bile. Re- 
cent studies have suggested that copper may be passed 
into the bile by lysosomal exocytosis or by the action 
of the recently discovered Cu-transporting P-type 
ATPases [73]. It can also come in the protein-bound 
form that is deposited in the bile as a result of protein 
catabolism and pinocytosis by the hepatic lysosomes. 
Urinary copper excretion is negligible under nor- 
mal conditions [74] since most of the copper in 
circulating blood is bound to ceruloplasmin or con- 
fined within the erythrocytes and very little copper 
permeates the glomerular capillaries. The small frac- 
tion of ingested copper that does appear in urine most 
likely come from the amino acid-bound fraction of 
plasma as well as from dissociation of copper-al- 
bumin complex. Urinary copper excretion contributes 
little to the maintenance of copper homeostasis. How- 
ever, cupruria generally occurs during the advanced 
stages of pathological conditions affecting the pri- 
mary homeostatic mechanisms such as biliary copper 
excretion, copper storage and ceruloplasmin synthe- 
sis. 
3. Wilson disease 
Wilson disease is an autosomal recessive disorder 
of copper transport first characterized by Kinnear 
Wilson [75] as involving an accumulation of copper 
in the liver and brain of affected individuals. Excel- 
lent reviews and monographs on the clinical and 
biochemical aspects of Wilson disease have been 
written, and the reader is referred to these for a more 
detailed treatment of these aspects of the disease 
[12,76,77]. Patients with Wilson disease can be 
broadly divided into three groups: those displaying 
hepatic symptoms, those displaying neurological 
symptoms, and those displaying both neurologic and 
hepatic symptoms. Wilson disease displays extensive 
clinical heterogeneity, with symptoms that are largely 
non-specific, making the diagnosis of the disease 
difficult for all except the most experienced physi- 
cians. The age of onset for Wilson disease extends 
from the age of 8 or 9 years to the mid-50's. Patients 
with Wilson disease are usually diagnosed with some 
form of hepatic dysfunction i  their early teens [78]. 
The spectrum of symptoms which can be directly 
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attributed to liver dysfunction are varied and can 
include jaundice, asymptomatic cirrhosis, chronic ag- 
gressive hepatitis, and subacute hepatitis (non-A or B 
hepatitis) [79]. In addition to the hepatic symptoms a 
small proportion of patients (approx. 20%) develop 
bone and joint disorders such as osteoporosis, and 
arthritis in the late stages of the disease [80]. 
The progression of Wilson disease can be divided 
roughly into three stages. In the first stage, copper 
accumulates in the cytosol of hepatocytes. In the 
second stage, increasing cytosolic opper levels cause 
the cells to begin to move some of the copper into 
lysosomes probably in the form of copper metallo- 
thionein [81]. The high levels of copper lead to 
hepatic necrosis and the release of large amounts of 
non-ceruloplasmin copper into the bloodstream. This 
rapid rise in serum copper causes damage to erythro- 
cyte membranes leading to hemolytic anemia [79,80]. 
The last stage of the disease involves accumulation i  
other organs such as the brain, kidneys, and cornea. 
Deposition of copper in the limbus of the cornea 
gives rise to the dull-yellow Kayser-Fleischer rings 
which are the hallmark of Wilson disease [76]. These 
rings are present in 95% of all Wilson patients and in 
100% of patients with neurological disorders [12]. In 
the later stages of the disease deposition of copper in 
the brain gives rise to neurological disturbances. This 
is consistent with the observation that symptoms of 
hepatic dysfunction are more common in patients 
with an early age of onset, while neurological symp- 
toms usually predominate in patients with a later age 
of onset [8,82]. The neurological symptoms associ- 
ated with Wilson disease are highly varied and may 
include deteriorating coordination, tremors, dys- 
arthria, dementia, drooling, personality changes, slur- 
ring of speech, behavioral problems, and rigidity 
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Fig. 2. Disruption of copper homeostasis in Wilson disease. In Wilson disease uptake of copper by the intestine and the liver is normal, 
however; biliary copper excretion and copper incorporation i to ceruloplasmin (Cp) is impaired. Severely decreased biliary excretion 
leads to a dramatic increase in cytosolic opper levels which leads to a large increase in the amount of copper bound to metallothionein 
(MT). As the disease progresses, increasing liver damage leads to the release of large amounts of non-ceruloplasmin-bound copper which 
accumulate inperipheral organs uch as the brain, kidneys and cornea. Deposition of copper in the cornea leads to Kayser-Fleischer rings 
which are characteristic of Wilson disease. 
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[79,83]. Neurological symptoms in many of these 
patients have been attributed to extrapyramidal in- 
volvement, cerebellar involvement or both [80]. 
Biochemical findings in patients with Wilson dis- 
ease indicate a disturbance in the homeostasis of 
copper levels in the body (Fig. 2). The excretion of 
copper is altered with a decrease in biliary excretion 
and an increase in urinary excretion [84]. Serum 
ceruloplasmin levels are decreased resulting in an 
increase of copper bound to albumin and low molecu- 
lar weight complexes, however; overall serum copper 
levels are lowered [85]. The brain, liver and kidneys 
all have greatly increased copper levels [78]. The 
accumulation of copper in the kidneys gives rise to 
renal dysfunction which may take the form of albu- 
minuria, or renal rickets leading to elevated copper 
levels in the urine. Defective biliary excretion of 
copper may be the single most important cause of 
copper accumulation i  Wilson disease [82]. This is 
most likely the result of a defect in the transport of 
copper into the bile canaliculi where bile is formed. 
This notion is supported by recent work which has 
suggested that the Wilson copper-ATPase is responsi- 
ble for transporting copper across the canalicular 
membrane into bile [73]. Ceruloplasmin is a secreted 
blue copper glycoprotein which accounts for the ma- 
jor amount of copper in the plasma. The low cerulo- 
plasmin levels found in Wilson disease are the result 
of a disturbance in the transfer of copper to the 
apo-protein during its synthesis in the cytoplasm. 
Studies on the incorporation of copper into apoceru- 
loplasmin suggest that incorporation takes place early 
in the biosynthetic pathway, possibly in the rough 
endoplasmic reticulum and that N-glycosylation is 
not required for copper loading [86]. 
The crystal structure of holoceruloplasmin has re- 
cently been solved [87]. The holo-protein contains ix 
copper atoms, three of which are involved in a trinu- 
clear copper cluster. The proposed function of cerulo- 
plasmin in humans is still under debate and include 
roles in copper transport [47,48,50,88,89] and be- 
cause of its ferroxidase activity, iron metabolism 
[90-92]. It has been shown that mutations in the 
ceruloplasmin gene can result in a condition known 
as aceruloplasminemia [92]. Patients stricken with 
this condition develop diabetes, neurologic disease, 
and retinal degeneration i addition to accumulating 
iron in the brain [92]. However, copper transport and 
homeostasis are unaffected. Iron accumulation or 
symptoms consistent with iron overload, have not 
been demonstrated in Wilson patients which suggests 
that the residual amount of ceruloplasmin being pro- 
duced is sufficient o maintain iron homeostasis. 
Treatments for Wilson disease have centered 
around chelation therapy aimed at mobilizing copper 
from affected organs and promoting its excretion 
through the urine. The first such chelating agents to 
be used in the treatment of Wilson disease was BAL 
(2,3-dimercaptopropanol) [93]. Significant clinical 
improvement in patients using BAL were only ob- 
served after long-term use, and were less significant 
in more acute cases of the disease [17]. However, 
patients had to deal with painful intramuscular injec- 
tions and often toxic side effects. The next major 
chelating agent used to treat Wilson disease was 
D-penicillamine [94]. D-penicillamine is superior to 
BAL as a chelating agent in that it can be adminis- 
tered orally, is less toxic and more effective. The 
standard ose of D-penicillamine for adults is 500 mg 
twice daily. On this dose, urinary excretion of copper 
can increase to between 4 and 5 mg per day [95]. 
Treatment with D-penicillamine usually lasts for a 
lifetime and produces ignificant clinical and biologi- 
cal improvements in a large number of cases. In some 
patients neurological symptoms may disappear, liver 
function may return to normal, and Kayser-Fleischer 
rings usually fade and then disappear [96]. However, 
as with most drugs, there are always some side 
effects and D-penicillamine is no exception. The most 
common side effects in the early stages of treatment 
include fever, anorexia, pyridoxine deficiency, and a 
mild depression of leukocyte and platelet counts 
[79,95,97]. In very few cases serious toxic effects 
may include systemic lupus erythematosus, and 
Goodpasture's syndrome [79,95]. There are also at 
least two cases on record of asymptomatic Wilson 
disease patients experiencing severe neurological de- 
terioration soon after the initiation of D-penicillamine 
therapy [98,99]. 
In  cases where patients develop toxic reactions to 
D-penicillamine or treatment is interrupted, alternate 
chelating agents have been successfully employed. 
Among these are trientine (triethylenetetramine dihy- 
drochloride) [100,101], tetrathiomolybdate [102,103], 
and zinc therapy [104-107]. Trientine has also been 
successfully employed in one female patient during 
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pregnancy who had previously been on D-penicilla- 
mine without adverse affects on the fetus [108]. 
Unilike other chelating agents which promote the 
excretion of copper through urine, zinc therapy pro- 
motes fecal copper excretion. Zinc is thought to 
promote copper excretion by inducing the synthesis 
of metallothionein i  the intestine thereby blocking 
the absorption of copper [109]. Although zinc has a 
greater ability to induce metallothionein synthesis 
than does copper, metallothionein has a higher affin- 
ity for copper than zinc [110]. Thus the induced 
metallothionein sequesters copper in the upper intes- 
tine thereby preventing its transfer into the portal 
circulation. The sloughing off of the intestinal cells 
into the lumen results in the elevated copper levels 
observed in the feces of zinc treated Wilson patients 
[110,111]. Patients with acute liver failure and en- 
cephalopathy may be beyond the help of chelation 
therapy. In these cases liver transplantation may pro- 
vide the only hope for survival. The results of 57 
Wilson patients who underwent liver transplantation 
showed that there was a 72% survival rate after the 
first year, with 4 patients requiring retransplantation 
[79,112]. 
Renewed interest in the field of copper metabolism 
has been generated by the recent identification of the 
gene responsible for Wilson disease (WND). The 
Wilson disease gene had previously been mapped to 
the q14.3 region of chromosome 13 by several groups 
[ 113-116]. Using this information as a roadmap three 
groups independently isolated the gene responsible 
for Wilson disease [4-7]. The Wilson disease gene 
has been shown to span at least 80 kb of genomic 
DNA and is comprised of 21 exons [117]. Sequence 
analysis of the cDNA indicates that it encodes a 1411 
amino acid P-type ATPase most likely involved in 
the transport of copper cations [4,5]. Northern blot 
analysis has revealed that the Wilson disease gene is 
expressed predominantly in the liver, kidney, and 
placenta [4,5]. This finding complements he bio- 
chemical and clinical evidence which indicates the 
involvement of these organs in the disease process. 
The predicted protein contains conserved omains 
for transduction, phosphorylation, and ATP binding 
found in other members of the P-type ATPase family 
[4,5,117]. In addition, the N-terminus of the protein 
contains ix tandemly repeated metal binding motifs 
of about 30 amino acids, each containing a 
GMTCXXC motif (Fig. 3). This motif is also present 
in the metal binding domains of other proteins uch 
as CadA from Staphylococcus aureus [118], and the 
copper transporting P-type ATPases CtaA and CopA 
from Synechococcus 7942 [119] and Enterococcus 
hirae [120] respectively. The Wilson disease protein 
has a high degree of identity to that coded by the 
gene involved in Menkes disease. The overall identity 
between the two ATPases is 57%, however; this 
figure rises to 79% and higher in the phosphatase, 
transduction-phosphorylation, and the ATP and metal 
binding domains [4]. Of the mutations discovered in 
the Wilson disease gene thus far, two specific mis- 
sense mutations are found in 38% of patients of 
COOH 
I I PhosphorylationlATP Binding 
Copper Binding 
Fig. 3. Predicted structure of the Wilson/Menkes disease copper-transporting P-Type ATPase. The predicted structure contains domains 
which are common to other cation transporting P-type ATPases. In addition the N-terminus contains ix repeats of a 30 amino acid 
putative copper binding motif. The gray transmembrane s gment contains a conserved Cys-Pro-Cys motif which is present in the 
transduction domain of other bacterial heavy metal ATPases. 
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European origin [121]. The remainder consist of in- 
sertion/deletion, nonsense, and splice site mutations 
which give rise to non-functional proteins. 
The Long-Evans Cinnamon (LEC) rat has been 
identified as an animal model of Wilson disease 
[122-124]. LEC rats display many of the biochemical 
and pathological features present in human Wilson 
disease patients. The Wilson disease gene and its rat 
counterpart are highly homologous, however; the rat 
gene is apparently missing the fourth copper binding 
domain while still maintaining the overall size of the 
gene [123]. Studies have indicated that LEC rats have 
impaired expression of the Wilson disease gene, ex- 
cess hepatic copper accumulation, defective biliary 
excretion of copper, and decreased holoceruloplasmin 
biosynthesis [122,125,126]. In addition it has been 
shown that copper is not incorporated into newly 
synthesized apoceruloplasmin in the golgi of LEC rat 
hepatocytes [127]. The LEC rat together with other 
animal models of Wilson disease such as the toxic 
milk mouse [128] and the bedlington terrier [129- 
131 ], are important research tools which will provide 
many insights into Wilson disease in humans. 
4. Menkes disease 
Menkes disease was first described by John Menkes 
in 1962 [132]. The disease was characterized in five 
patients of the same family who all died before the 
age of three years. All five patients displayed similar 
clinical symptoms which Menkes and coworkers used 
to define the disease. Pedigree analysis of the family 
revealed that the disease seemed to be limited to 
males and inherited in a sex-linked recessive manner. 
Onset of the disease was found to occur very early in 
life, possibly starting in utero. All five patients were 
delivered without any problems except for one case 
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Fig. 4. Disruption of copper homeostasis in Menkes disease. In Menkes disease absorption of copper in the gastrointestinal tr ct is 
severely impaired. The increasing amounts of copper in the intestinal lumen lead to the induction of metallothionein and the storage of 
copper as the copper-metallothionein complex. Copper uptake and excretion by the liver are normal as are copper enzyme l vels. The 
severely decreased intestinal bsorption of copper gives rise to a shortage of exchangeable copper followed by a deficiency of 
developmentally important cuproenzymes. Uptake by peripheral tissues i normal however, excretion and intracellular copper trafficking 
are disrupted by mutations in the Menkes copper-ATPase g ne. As a result of impaired copper efflux, peripheral tissues in Menkes 
patients end to accumulate copper in the form of copper-metallothionein. 
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in which the patient was born by breech delivery. 
Birthweights were normal, however; all patients 
gained very little weight in the months following 
birth despite maintaining a normal diet. Hair abnor- 
malities were present in all the affected children 
either at birth or appearing three months thereafter. 
To the touch the hair appears coarse and brittle and 
possesses an ivory-white colour due to depigmenta- 
tion. Microscopic analysis of individual hair strands 
revealed that they were either twisted (pili torti) of 
varying caliber (monilethrix), or fractured at regular 
intervals (trichorrhexis nodosa). Despite these gross 
abnormalities, the level of sulfhydryls in the hair 
were found to be normal [132]. Two of the five 
patients also displayed the associated conditions of 
albuminuria nd aminoaciduria. 
All patients developed seizures between the ages 
of two to fifteen months. Postmortem analysis of two 
patients howed widespread egeneration in the cere- 
brum and cerebellum with overall brain size being 
significantly smaller than average. The years follow- 
ing the initial characterization f the disease saw an 
increase in the number of case reports conforming to 
the original description of the disease. These reports 
expanded the range of clinical features to include 
hypothermia, thrombosis, hyperbilirubinemia, bone 
changes, arterial rupture, and characteristic facies, as 
well as confirming the pattern of inheritance origi- 
nally observed by Menkes [133,134]. However, ten 
years would pass since Menkes' original observation 
of the disease before its basic biochemical defect 
would be identified as an impairment in the absorp- 
tion of copper [133,135]. Patients studied in this 
series were all found to have severe copper defi- 
ciency in the liver, brain and serum, however; red 
blood cells maintained normal copper levels. The low 
serum copper levels were also accompanied by very 
low ceruloplasmin levels. Oral administration of cop- 
per did not elevate serum-copper levels, however; 
intravenous injection of copper was able to elevate 
ceruloplasmin levels and clearance from serum was 
normal [135]. These results together with the finding 
of drastically reduced absorption of orally adminis- 
tered copper strengthened the notion that reduced 
intestinal absorption of copper may be responsible for 
the main features of the disease. 
Further work suggested that the main clinical fea- 
tures of the disease result not only from impaired 
copper absorption but also from a severe disturbance 
in the intracellular t ansport of copper [136,137] (Fig. 
4). Studies on cultured fribroblasts from Menkes 
patients have shown an increase in the accumulation 
of radioactive copper as well as increased levels of 
intracellular copper [138-140]. The accumulated cy- 
tosolic copper has been shown to exist as a copper 
metallothionein [ 141,142], and the induction of metal- 
lothionein in cultured muscle cells from Menkes pa- 
tients is elevated relative to normal cells [143]. In 
addition, analysis of the copper levels in the mito- 
chondria extracted from cultured fibroblasts from 
Menkes patients indicated that they are in a state of 
copper deficiency [63]. 
In Menkes patients copper is incapable of being 
absorbed from the digestive system and hence passed 
into the blood stream for distribution to other organs. 
Rather, copper becomes trapped in the intestinal mu- 
cosa in the form of copper metallothionein which is 
excreted from the body when these cells are sloughed 
off. The lack of available copper in affected individu- 
als leads to a severely decreased levels of develop- 
mentally important cuproenzymes (Table 1). A defi- 
ciency in enzymes uch as lysyl oxidase, tyrosinase, 
cytochrome c oxidase, dopamine /3-hydroxylase, su- 
peroxide dismutase, and amine oxidase, are thought 
to account for the major clinical features of the 
disease [12,144]. Lysyl oxidase is an important en- 
zyme in the crosslinking of collagen and elastin, a 
deficiency in this enzyme would explain the connec- 
tive tissue defects observed in Menkes patients. 
Severely decreased levels of this enzyme have been 
demonstrated in tissues and cultured cells from 
Menkes patients [12,145,146]. Low levels of cy- 
tochrome c oxidase can lead to temperature instabil- 
ity, while tyrosinase deficiency explains the hair de- 
pigmentation observed in affected individuals [147]. 
It is interesting to note that studies in murine models 
of Menkes disease have shown normal activity of 
cuproenzymes in the liver despite severely depressed 
copper levels in this organ [148]. This observation 
suggests that intracellular copper transport in the liver 
is unaffected in Menkes disease patients. 
The recent isolation of the gene responsible for 
Menkes disease has generated an extensive interest in 
the area of intracellular copper transport. The Menkes 
(MNK) gene had previously been mapped to the 
Xql3 region of the X-chromosome [149,150]. Using 
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this information as a guide the gene responsible for 
Menkes disease was isolated independently b  three 
groups [1-3]. Analysis of the cDNA sequence re- 
vealed that it codes for a 1500 amino acid protein, 
predicted to be a P-type ATPase responsible for the 
translocation of copper across membranes [3]. The 
predicted protein contains domains which are homol- 
ogous to those found in other cation transporting 
ATPases. In addition the N-terminus contains six 
metal-binding motifs which are highly homologous to 
those found in bacterial metal transporters 
[1,3,151,152]. Northern blot analysis has indicated 
that the Menkes disease gene is expressed in all 
tissues except he liver [1,3]. The pattern of expres- 
sion is consistent with clinical and biochemical fea- 
tures of the Menkes phenotype. 
Approximately 15-20% of the mutations in pa- 
tients with classical Menkes disease are deletions of 
varying sizes [1-3]. Further studies have identified 
nonsense, missence, deletion and splice-site muta- 
tions which, in many patients, lead to exon skipping 
[153]. However, it is interesting to note that not all 
splice-site mutations give rise to the classical form of 
Menkes disease. Several splice-site mutations have 
been shown to give rise to the less severe forms of 
Menkes disease such as X-linked cutis laxa and 
occipital horn syndrome [154,155]. These conditions 
are characterized by connective tissue abnormalities 
such as hyperelastic skin in the former, and a bony 
abnormality of the skull (occipital exostoses) in the 
latter [12,156]. The other hallmarks of Menkes dis- 
ease are not present in these conditions. This would 
seem to indicate that lysyl oxidase is especially sensi- 
tive to disturbances in intracellular copper homeosta- 
sis relative to other cuproenzymes. 
Treatments for Menkes patients have concentrated 
on restoring normal copper levels in the body by 
administering copper. Since intestinal copper absorp- 
tion is extremely low in Menkes patients the copper 
must be administered parenterally. Copper has been 
administered in various forms including copper chlo- 
ride, copper sulfate, copper EDTA, and copper albu- 
min. However, it has been found that these com- 
plexes are unable to produce significant clinical im- 
provement especially in regards to neurodegeneration 
[157]. However, a copper complex which has been 
used to treat Menkes disease is copper-histidine [30]. 
Copper-histidine is a normal component of human 
serum and has been shown to play an important role 
in the transport and uptake of copper [23,40,158]. 
Uptake studies conducted in vitro have suggested that 
copper uptake by brain tissue is mediated by com- 
plexation to histidine [39,159-161]. 
Patients treated with subcutaneous injections of 
copper-histidine have shown significant clinical and 
biochemical improvement [32,33,162]. These case 
studies have shown a normalization of serum copper, 
ceruloplasmin, dopamine and norepinephrine l vels 
after three months of treatment [162]. The normaliza- 
tion of dopamine and norepinephrine l vels indicate 
that normal dopamine/3-hydroxylase ev ls may have 
been achieved. The severity of Menkes disease in two 
patients who responded very well to copper-histidine 
treatment has been confirmed by DNA sequence 
analysis. It has recently been shown that these two 
patients have mutations in the Menkes gene which 
result in the production of an ATPase which lacks the 
ATPase 'core' [34]. Despite significant improvements 
in these patients, connective tissue disorders continue 
to persist indicating that lysyl oxidase levels are not 
being restored by copper-histidine injections. It may 
be that copper presented in this form is unavailable 
for incorporation into lysyl oxidase. Studies in 
brindled mice, a murine model for Menkes disease, 
have shown that subcutaneous injections of copper(I) 
in alkyl polyether/sebacic a id solution are able to 
dramatically increase the levels of lysyl oxidase [163]. 
This finding suggests that the oxidation state of cop- 
per may affect its mobility into certain intracellular 
compartments and that treatment of patients with 
both copper(I) and copper(II) complexes may be 
more effective than either alone. 
The mottled mutants in mice have been identified 
as murine models of Menkes disease and occipital 
horn syndrome since the 1950s [134,164,165]. Ge- 
netic analysis of these mice following the isolation of 
the Menkes disease gene in humans has shown that 
the mottled gene is homologous to the MNK gene in 
humans with parallel expression patterns [166]. The 
presence of RNA splicing defects imilar to those in 
the human MNK gene have also been identified 
[167]. The predicted amino acid sequence from the 
mottled gene shows approximately 90% identity to its 
human homologue [167]. The mechanism by which 
these genes are regulated in both humans and mice 
has yet to be discovered. Surprisingly, it has recently 
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been shown that cellular copper levels have no effect 
on the expression level of the Menkes gene homo- 
logue in various mouse tissues [168]. 
5. Future perspectives 
The isolation of the genes for both Menkes and 
Wilson diseases has added another piece to the solu- 
tion of the copper transport puzzle. However, much 
work remains to be done in order to determine the 
specific role played by these gene products in the 
homeostatic ontrol of copper in the body. Specifi- 
cally, the intracellular localization of these gene prod- 
ucts will be a very important first step in understand- 
ing their function. These studies will be key in deter- 
mining how the transport of copper is interrupted by 
mutations in the ATPase gene. Research will also 
need to be carried out which will address the ques- 
tions of the kinetics and mechanism of copper trans- 
port through these ATPases. These data will be key 
to the development of new therapeutic agents for the 
treatment of both Menkes and Wilson diseases. An- 
other important area for study will be the structural 
aspects of the pump and its various domains. With 
detailed structural information in conjunction with 
kinetic and functional data, it will then be possible to 
construct a detailed picture of the copper transport 
process through the ATPase. The next few years in 
the area of copper transport and homeostasis will be 
very exciting indeed. 
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